CTRI/2021/08/036043尚未招募2 期
A Randomized, Parallel Group, Open Label, Standard Controlled Clinical Study to Compare the Efficacy and Safety of Unani Formulation - Roghan-i Zarneekh (T) with Luliconazole (T) in the Management of QÅ«bÄ? (Dermatophytosis)
ational Research Institute of Unani Medicine for Skin Disorders0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •The partcipants will be included in the study on the basis of the following criteria:
- •i. Participants with positive mycology (KOH positive)
- •ii. Circumscribed lesions having any of the
- •following signs and symptoms on trunk and inguinal region:
- •a. Presence of pruritus and burning
- •b. Presence of scales
- •c. Presence of central clearing
- •d. Erythematous papules
排除标准
- •The partcipants will be excluded:
- •i. Co-morbid conditions of the participants
- •ii. Pregnant or Lactating Women
- •iii. Significant pulmonary/ cardiovascular/ hepatorenal dysfunction
- •iv. Known cases of Immuno-compromised states (HIV/ AIDS, etc.), malignancies
- •v. History of Hypersensitivity to Luliconazole
- •vi. Participants not willing to attend treatment schedule regularly
- •vii. Participants using the following medications:
- •a. Systemic antifungal within 15 days of baseline visit
- •b. Systemic corticosteroids within 15 days of baseline visit
研究者
相似试验
尚未招募
2 期
A Clinical Study to assess Effectiveness of Unani formulations in pityriasis versicolorCTRI/2020/06/026209ational Research Institute of Unani Medicine for Skin Disorders Hyderabad
尚未招募
2 期
unani treatment of Kathra al-Bawl (Overactive Bladder) with Jawarish Kundur and OxybutyniCTRI/2023/03/050407Central Council for research in Unani Medicine
进行中（未招募）
不适用
A Randomized, Open Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non Small Cell Lung Cancer who have Previously Received Platinum Based Chemotherapy - INTERESTocally Advanced or Metastatic Recurrent Non-Small Cell Lung CancerEUCTR2004-002943-28-LVAstraZeneca AB1,440
进行中（未招募）
不适用
An Open Label, Randomised, Parallel Group, Multicentre Study toCompare ZOLADEX™ 10.8 mg Given Every 12 Weeks with ZOLADEX3.6 mg Given Every 4 Weeks in Pre-menopausal Women with OestrogenReceptor Positive Advanced Breast CancerEUCTR2005-004001-29-CZAstraZeneca AB260
未知
3 期
An Open Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women With Oestrogen Receptor Positive Advanced Breast CancerBreast CancerJPRN-jRCT2080221070AstraZeneca